Comparing RA Medical Systems (RMED) and Its Rivals
RA Medical Systems (NYSE: RMED) is one of 120 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare RA Medical Systems to similar businesses based on the strength of its institutional ownership, dividends, analyst recommendations, valuation, risk, profitability and earnings.
This table compares RA Medical Systems and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RA Medical Systems||N/A||N/A||N/A|
|RA Medical Systems Competitors||-30.00%||-41.48%||-13.59%|
This table compares RA Medical Systems and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|RA Medical Systems||$6.26 million||-$30.83 million||-1.14|
|RA Medical Systems Competitors||$1.48 billion||$146.48 million||43.94|
RA Medical Systems’ competitors have higher revenue and earnings than RA Medical Systems. RA Medical Systems is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for RA Medical Systems and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RA Medical Systems||0||0||4||0||3.00|
|RA Medical Systems Competitors||799||2804||4974||252||2.53|
RA Medical Systems presently has a consensus target price of $14.75, suggesting a potential upside of 286.13%. As a group, “Surgical & medical instruments” companies have a potential upside of 21.76%. Given RA Medical Systems’ stronger consensus rating and higher possible upside, analysts plainly believe RA Medical Systems is more favorable than its competitors.
Insider and Institutional Ownership
31.9% of RA Medical Systems shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.8% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
RA Medical Systems Company Profile
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.